Financial Performance - The company's operating revenue for 2024 reached ¥1,320,761,061.74, representing a 10.16% increase compared to ¥1,198,902,103.15 in 2023[25] - The net profit attributable to shareholders for 2024 was ¥62,637,482.98, a decrease of 22.39% from ¥80,706,911.48 in 2023[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,154,344.46, down 40.36% from ¥42,178,764.38 in 2023[25] - The net cash flow from operating activities increased by 27.22% to ¥195,407,571.77 in 2024, compared to ¥153,592,321.71 in 2023[25] - The total assets at the end of 2024 were ¥2,981,000,556.19, a decrease of 1.75% from ¥3,034,057,625.33 at the end of 2023[25] - The net assets attributable to shareholders increased by 1.72% to ¥1,737,720,580.05 at the end of 2024, compared to ¥1,708,293,232.64 at the end of 2023[25] - The basic earnings per share for 2024 were ¥0.25, down 21.88% from ¥0.32 in 2023[26] - The diluted earnings per share for 2024 were also ¥0.25, reflecting a 21.88% decrease from ¥0.32 in 2023[26] - The weighted average return on net assets for 2024 was 3.64%, a decrease of 1.18 percentage points from 4.82% in 2023[26] Revenue Breakdown - The enzyme preparation business generated revenue of CNY 50,474.96 million, with a year-on-year increase of CNY 6,330.11 million, representing a growth rate of 14.34%[32] - The company's main business income reached CNY 1,281,793,748.24, an increase of 8.86% year-on-year, while the main business cost rose by 11.53% to CNY 712,125,052.30[69] - The revenue from overseas markets was 99,948,895.67, showing a significant increase of 19.98% year-over-year[71] - Domestic sales accounted for 1,181,844,852.57, representing an 8.02% increase from the previous year[71] Research and Development - Research and development expenses amounted to CNY 11,822.23 million, accounting for 8.95% of operating revenue, with a year-on-year growth of 6.81%[32] - The company invested CNY 118.22 million in R&D, accounting for 8.95% of its revenue, which is considered high in the industry[58] - The company has established six technology centers and two key laboratories, employing 266 dedicated R&D personnel[56] - The company has developed a high-throughput screening technology platform for microbial strains, enhancing its ability to innovate and apply new products across various sectors[45] - The company is actively developing new animal vaccines and antibiotic enhancement platforms to improve clinical outcomes and reduce antibiotic resistance[61] Market Trends and Opportunities - The enzyme and micro-ecological agent industry is in a growth phase, benefiting from increasing national emphasis on safety and environmental protection[38] - The demand for enzyme preparations is expected to continue growing due to increasing environmental protection standards and policies promoting carbon neutrality[39] - The global probiotics market is rapidly growing, with applications expanding beyond gut health to include weight management and skin health, indicating a shift towards high-value product development in the food industry[41] - The agricultural sector faces significant challenges due to soil degradation and pesticide residues, creating opportunities for microbial preparations and bio-fertilizers to improve soil health and sustainability[41] Corporate Governance and Management - The total remuneration for the board members and senior management during the reporting period amounts to CNY 568.83 million[154] - The company has maintained strict confidentiality obligations during the preparation of regular reports and significant matters, with no leakage incidents reported[153] - The total number of shares held by all board members and senior management remains unchanged at 17,409,720 shares[154] - The company held six board meetings during the year, with all directors attending[160] Environmental Initiatives - The company invested 1,178,300 RMB in environmental protection during the reporting period[189] - The company’s enzyme products are estimated to have reduced carbon dioxide emissions by approximately 2.5919 million tons in downstream applications[191] - The application of microbial agents in agriculture can fundamentally reduce the use of chemical fertilizers and pesticides, thus minimizing soil and water pollution[194] Future Outlook - The company aims to leverage its R&D capabilities to ensure steady growth in performance through innovative product offerings and market expansion strategies[103] - The company is committed to building a fair organizational environment and enhancing employee satisfaction through various development programs and cultural activities[197] - The company plans to enhance its traditional Chinese medicine production processes and expand into upstream raw material businesses to reduce costs and improve quality[143]

Financial Performance - The company's revenue for Q1 2025 was CNY 310,197,929.93, representing an increase of 8.16% compared to CNY 286,784,227.66 in the same period last year[3] - Net profit attributable to shareholders decreased by 24.73% to CNY 9,576,827.68 from CNY 12,722,943.82 year-on-year[3] - The net profit excluding non-recurring gains and losses increased by 45.44% to CNY 5,259,509.61, driven mainly by government subsidies and reduced financial income[6] - Total operating revenue for Q1 2025 reached ¥310,197,929.93, an increase of 8.8% compared to ¥286,784,227.66 in Q1 2024[16] - Net profit for Q1 2025 was ¥16,586,362.18, a decrease of 3.4% from ¥17,162,518.08 in Q1 2024[16] - The basic earnings per share decreased by 20.00% to CNY 0.04 from CNY 0.05 in the same period last year[3] - Earnings per share for Q1 2025 were ¥0.04, down from ¥0.05 in Q1 2024[17] Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY 7,617,106.76, a 156.39% increase from a negative cash flow of CNY 13,507,477.33 in the previous year[3] - The net cash flow from operating activities for Q1 2025 was ¥7,617,106.76, compared to a negative ¥13,507,477.33 in Q1 2024, indicating a significant improvement[19] - Cash inflow from operating activities totaled ¥384,525,708.67 in Q1 2025, up from ¥317,112,598.93 in Q1 2024, representing an increase of approximately 21.2%[19] - The total cash outflow from operating activities increased to ¥376,908,601.91 in Q1 2025 from ¥330,620,076.26 in Q1 2024, reflecting a rise of about 14%[19] - The net cash flow from financing activities improved to ¥66,632,426.50 in Q1 2025, compared to ¥39,280,028.59 in Q1 2024, showing an increase of about 69.9%[20] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 3,025,202,671.63, up 1.48% from CNY 2,981,000,556.19 at the end of the previous year[4] - Total liabilities increased to ¥1,147,176,454.05 from ¥1,110,984,258.58, marking a rise of 3.2%[13] - The company reported a total asset of ¥3,025,202,671.63 as of the end of the reporting period, compared to ¥2,981,000,556.19 previously[14] Shareholder Information - The company reported a total of 19,490 common shareholders at the end of the reporting period[8] - The largest shareholder, Qingdao Kangdian Industrial Co., Ltd., holds 44.4% of the shares, totaling 112,407,400 shares[9] - Shareholders' equity attributable to shareholders increased slightly by 0.55% to CNY 1,747,247,606.63 from CNY 1,737,720,580.05[4] - The total equity attributable to shareholders rose to ¥1,747,247,606.63 from ¥1,737,720,580.05, showing a slight increase of 0.3%[13] Operational Costs and Expenses - Total operating costs for Q1 2025 were ¥293,945,014.79, up from ¥273,764,144.88 in Q1 2024, reflecting a rise of 7.4%[16] - Research and development expenses for Q1 2025 were ¥28,494,054.14, compared to ¥26,717,261.31 in Q1 2024, indicating a growth of 6.6%[16] - The company's cash flow statement for Q1 2025 indicates a focus on maintaining liquidity amid rising operational costs[18] Investment Activities - Cash flow from investment activities showed a net outflow of ¥82,838,281.86 in Q1 2025, compared to a net outflow of ¥64,984,676.57 in Q1 2024, indicating a worsening investment cash flow situation[20] - The cash inflow from investment activities in Q1 2025 was ¥242,602,714.00, a substantial increase from ¥17,749,411.51 in Q1 2024[20] - The cash outflow from investment activities rose significantly to ¥325,440,995.86 in Q1 2025 from ¥82,734,088.08 in Q1 2024, marking an increase of approximately 293%[20] Overall Trends - The company’s cash flow from operating activities has shown a positive trend, while investment activities have resulted in increased cash outflows, necessitating strategic adjustments[19][20]

青岛蔚蓝生物股份有限公司关于收购 青岛润博特生物科技有限公司 2024 年 度业绩承诺实现情况的说明 审核报告 致同会计师事务所（特殊普通合伙） 目 录 经审核，我们认为，蔚蓝生物公司管理层编制的业绩承诺实现情况说明 已按照《上海证券交易所上市公司自律监管指引第 1号——规范运作》的规定 编制，在所有重大方面公允反映了青岛润博特生物科技有限公司实际盈利数 与股东对公司业绩承诺的差异情况。 按照《上海证券交易所上市公司自律监管指引第 1号——规范运作》的有 关规定，编制业绩承诺实现情况说明，保证其内容真实、准确、完整，不存 在虚假记录、误导性陈述或重大遗漏是蔚蓝生物公司管理层的责任，我们的 责任是在实施审核工作的基础上对蔚蓝生物公司管理层编制的业绩承诺实现 情况说明提出鉴证结论。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号—历史财务信息 审计或审阅以外的鉴证业务》的规定计划和实施审核工作，以合理确信业绩 承诺实现情况说明不存在重大错报。在审核工作中，我们结合青岛润博特生 物科技有限公司实际情况，实施了包括核查会计记录等我们认为必要的审核 程序。我们相信，我们的审核工作为提出鉴证结论提供了合理的基础 ...

青岛蔚蓝生物股份有限公司 二〇二四年度 内部控制审计报告 致同会计师事务所（特殊普通合伙） 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 内部控制审计报告 致同审字（2025）第 371A017996 号 青岛蔚蓝生物股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了青岛蔚蓝生物股份有限公司（以下简称蔚蓝生物公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是蔚蓝生物公司董事会的责任。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外， 由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的 程度降低，根据内部控制审计结果推测未来内部控制的有效性具有一 ...

中泰证券股份有限公司 1、实际募集资金金额及资金到账时间 经中国证券监督管理委员会证监许可[2018]1961号文核准，青岛蔚蓝生物股 份有限公司（以下简称"蔚蓝生物"或"公司"）由主承销商广发证券股份有限公司 采用网下向符合条件的投资者询价配售和网上向社会公众投资者定价发行相结 合的方式，向社会公众公开发行人民币普通股(A股)股票3,866.70万股，发行价为 每股人民币10.19元，共计募集资金394,016,730.00元，扣除各项发行费用后，实 际募集资金净额为人民币347,440,291.00元。上述募集资金已于2019年1月9日到 位，由瑞华会计师事务所（特殊普通合伙）进行了审验，并由其出具了《验资报 告》(瑞华验字[2019]37110002号)。公司已与保荐机构、募集资金专户开户银行 签署了《募集资金专户存储三方监管协议》，开设了募集资金专项账户，对募集 资金实行专户存储。2021年1月18日，由于保荐机构的更换，公司与本保荐机构、 募集资金专户开户银行重新签署了《募集资金专户存储三方监管协议》。 2、募集资金使用和结余情况 | 明细 | | | | 金额（元） | | --- | --- | ...

青岛蔚蓝生物股份有限公司 二〇二四年度 审计报告 致同会计师事务所（特殊普通合伙） 青岛蔚蓝生物股份有限公司全体股东： 一、审计意见 我们审计了青岛蔚蓝生物股份有限公司（以下简称蔚蓝生物公司）财务 报表，包括 2024 年 12月 31 日的合并及公司资产负债表，2024 年度的合并及公 司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财 务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了蔚蓝生物公司 2024 年 12 月 31 日的合并及公司财务状况以及 2024 年度的合并及公司经营成果和现金流量。 二、形成审计意见的基础 目 录 | 审计报告 | 1-6 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-106 | 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 ...

关于青岛蔚蓝生物股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 1-9 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 致同会计师事务所（特殊普通合伙） 目 录 关于青岛蔚蓝生物股份有限公司 2024 年度募集资金 存放与实际使用情况鉴证报告 青岛蔚蓝生物股份有限公司 2024 年度募集资金 存放与实际使用情况的专项报告 关于青岛蔚蓝生物股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同专字（2025）第 371A010665 号 青岛蔚蓝生物股份有限公司全体股东： 我们接受委托，对后附的青岛蔚蓝生物股份有限公司（以下简称 蔚蓝生 物公司）《2024 年度募集资金存放与实际使用情况的专项报告》（以下简称 "专项报告"）执行了合理保证的鉴证业务。 按照《上市公司监管指引第 2号——上市公司募集资金管理和使用的监管 要求（2022年修订）》和《上海证券交易所上市公司自律监管指引第 1号—— 规 ...

Group 1 - The company reported a revenue of 310 million yuan for the first quarter of 2025, representing a year-on-year increase of 8.16% [1] - The net profit for the same period was 9.5768 million yuan, showing a year-on-year decline of 24.73% [1]

一直在路上，所以停下脚步，只在于分享 包括： 新 材料/ 半导体 / 新能源/光伏/显示材料 等 添加 小编微信 ，遇见 志同道合 的你 写在前面 （文末有惊喜） 正文 = 在 1 is fo 基础化工 点击 最 下方 "在看"和" "并分享，"关注"材料汇 行业专题 以生物造万物. 构建 Al+新质生产力新业态 合成生物深度系列报告之一 主要观点: ● 合成生物学是生产力转型升级新方向 合成生物学是一门基于工程化的设计理念,结合生物学、化学、医 学、农学、工程学、计算机与数据科学等交叉学科技术,旨在设计 和构建新的生物系统,以实现特定的功能,其本质是让细胞为人类 工作生产想要的物质。合成生物学和发酵工程的区别在于是否对细 胞进行定向性干预,大幅提升微生物细胞工厂效率。目前合成生物 学可合成的大宗化学品仅几十种,在整体基础化学品中的占比还非 常有限,还无法颠覆性替代传统化工,但在部分领域有比较好的应 用场景,具有战略与商业角度的优势,生物制造未来提升空间巨 大。 ● Al 赋能上游+政策推动落地,合成生物学东风将至 当前,国际合成生物学优势力量主要分布在美、欧等地,其政策对 我国来说具备一定参考意义,国内也正 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]